Screenshot 2024 01 04 At 2.52.39 pm

GenFlow Bioscience named “a firm to watch” in 2024 by The Guardian

We are thrilled to be named “a firm to watch” by The Guardian. Undoubtedly, the success of our NASH studies this past year and the cutting-edge clinical trials we have planned for next year solidified our name on this list. To read more, click here

GenFlow Bioscience named “a firm to watch” in 2024 by The Guardian Read More »